3-quinolin-4-yl-propionic acid ethyl ester | 67752-33-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: 3-quinolin-4-yl-propionic acid ethyl ester
• 英文别名: Ethyl 3-(4-quinolinyl)propionate；4-Quinolinepropanoic acid, ethyl ester；ethyl 3-quinolin-4-ylpropanoate
• CAS: 67752-33-4
• 化学式: C₁₄H₁₅NO₂
• 分子量: 229.279
• InChiKey: AOXXHHKVRMCORY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  17
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  39.2
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  3-quinolin-4-yl-propionic acid ethyl ester 在 二异丁基氢化铝 作用下， 以 甲苯 为溶剂， 反应 2.0h， 以65%的产率得到3-(4-quinolinyl)propionaldehyde
  参考文献：
  名称：

  Anhydrolide Macrolides. 2. Synthesis and Antibacterial Activity of 2,3-Anhydro-6-O-methyl 11,12-Carbazate Erythromycin A Analogues

  摘要：

  A series of 3-descladinosyl-2,3-anhydro-6-O-methylerythromycin A 11,12-cyclic carbazate analogues was prepared and evaluated for antibacterial activity. These 2,3-anhydro macrolides were found to be potent antibacterial agents in vitro against macrolide-susceptible organisms including Staphylococcus aureus 6538P, Streptococcus pyogenes EES61, and Streptococcus pneumoniae ATCC6303. These compounds were also very active against some organisms that show macrolide resistance (S. aureus A5177, S. pyogenes PIU2584, and S. pneumoniae 5649). The compounds generally showed poor activity against organisms with constitutive MLS resistance. Selected compounds were evaluated in vivo in mouse protection studies. Although most of the compounds tested in vivo showed poor efficacy, two compounds, 38 and 57, were more active than clarithromycin against S. pneumoniae ATCC6303.

  DOI：

  10.1021/jm970548p
• 作为产物：
  描述：

  4-喹啉甲醛 在 palladium on activated charcoal 氢气 、 1,8-二氮杂双环[5.4.0]十一碳-7-烯 、 lithium chloride 作用下， 以 甲醇 、 乙腈 为溶剂， 反应 23.0h， 生成 3-quinolin-4-yl-propionic acid ethyl ester
  参考文献：
  名称：

  Anhydrolide Macrolides. 2. Synthesis and Antibacterial Activity of 2,3-Anhydro-6-O-methyl 11,12-Carbazate Erythromycin A Analogues

  摘要：

  A series of 3-descladinosyl-2,3-anhydro-6-O-methylerythromycin A 11,12-cyclic carbazate analogues was prepared and evaluated for antibacterial activity. These 2,3-anhydro macrolides were found to be potent antibacterial agents in vitro against macrolide-susceptible organisms including Staphylococcus aureus 6538P, Streptococcus pyogenes EES61, and Streptococcus pneumoniae ATCC6303. These compounds were also very active against some organisms that show macrolide resistance (S. aureus A5177, S. pyogenes PIU2584, and S. pneumoniae 5649). The compounds generally showed poor activity against organisms with constitutive MLS resistance. Selected compounds were evaluated in vivo in mouse protection studies. Although most of the compounds tested in vivo showed poor efficacy, two compounds, 38 and 57, were more active than clarithromycin against S. pneumoniae ATCC6303.

  DOI：

  10.1021/jm970548p

文献信息

• 3-DESCLADINOSE-2,3-ANHYDROERYTHROMYCIN DERIVATIVES
  申请人：ABBOTT LABORATORIES

  公开号：EP0922050B1

  公开（公告）日：2003-07-30
• US5750510A
  申请人：——

  公开号：US5750510A

  公开（公告）日：1998-05-12
• [EN] 3-DESCLADINOSE-2,3-ANHYDROERYTHROMYCIN DERIVATIVES<br/>[FR] DERIVES DE LA 3-DESCLADINOSE-2,3-ANHYDRO-ERYTHROMYCINE
  申请人：ABBOTT LABORATORIES

  公开号：WO1997042205A1

  公开（公告）日：1997-11-13

  (EN) Novel 3-descladinose-2,3-anhydroerythromycin compounds and pharmaceutically acceptable salts and esters thereof having antibacterial activity selected from the group consisting of: (a) (I), (b) (II), (c) (III), and (d) (IV), pharmaceutical compositions comprising a therapeutically effective amount of a compound of formulas (I)-(IV) of the invention in combination with a pharmaceutically acceptable carrier, as well as a method for treating bacterial infections by administering to a mammal a pharmaceutical composition containing a therapeutically-effective amount of a compound of formulas (I)-(IV) of the invention.(FR) L'invention concerne de nouveaux composés de la 3-descladinose-2,3-anhydro-érythromycine, leurs sels et leurs esters pharmaceutiquement acceptables, ayant une activité anti-bactérienne, choisis dans le groupe constitué de a) (I), b) (II), c) (III) et d) (IV); des compositions pharmaceutiques contenant une quantité thérapeutiquement efficace d'un composé de formule (I)-(IV) associé à un support pharmaceutiquement acceptable; ainsi qu'une méthode permettant de traiter les infections bactériennes en administrant à un mammifère une composition pharmaceutique contenant une quantité thérapeutiquement efficace d'un composé de formule (I)-(IV).